GC Cell Corporation (KOSDAQ: 144510)

South Korea flag South Korea · Delayed Price · Currency is KRW
23,350
-150 (-0.64%)
Jan 21, 2025, 3:00 PM KST
-41.41%
Market Cap 350.88B
Revenue (ttm) 184.36B
Net Income (ttm) -3.39B
Shares Out 15.03M
EPS (ttm) -225.52
PE Ratio n/a
Forward PE n/a
Dividend 100.00 (0.43%)
Ex-Dividend Date n/a
Volume 21,572
Average Volume 38,969
Open 23,450
Previous Close 23,500
Day's Range 23,350 - 24,050
52-Week Range 21,250 - 47,950
Beta 0.89
RSI 40.65
Earnings Date Feb 7, 2025

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Employees 752
Stock Exchange KOSDAQ
Ticker Symbol 144510
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.